Oculis Holding AG Ordinary shares
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b cli… Read more
Oculis Holding AG Ordinary shares (OCS) - Net Assets
Latest net assets as of September 2025: $130.59 Million USD
Based on the latest financial reports, Oculis Holding AG Ordinary shares (OCS) has net assets worth $130.59 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($167.84 Million) and total liabilities ($37.24 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $130.59 Million |
| % of Total Assets | 77.81% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Oculis Holding AG Ordinary shares - Net Assets Trend (2020–2024)
This chart illustrates how Oculis Holding AG Ordinary shares's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Oculis Holding AG Ordinary shares (2020–2024)
The table below shows the annual net assets of Oculis Holding AG Ordinary shares from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $73.38 Million | -21.71% |
| 2023-12-31 | $93.73 Million | +195.65% |
| 2022-12-31 | $-97.99 Million | -60.76% |
| 2021-12-31 | $-60.95 Million | -39.63% |
| 2020-12-31 | $-43.65 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Oculis Holding AG Ordinary shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 23182900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $446.00K | 0.61% |
| Other Comprehensive Income | $-2.50 Million | -3.41% |
| Other Components | $361.00 Million | 491.94% |
| Total Equity | $73.38 Million | 100.00% |
Oculis Holding AG Ordinary shares Competitors by Market Cap
The table below lists competitors of Oculis Holding AG Ordinary shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Seers Technology
KQ:458870
|
$1.05 Billion |
|
Dorian LPG Ltd
NYSE:LPG
|
$1.05 Billion |
|
HC Semitek Corp
SHE:300323
|
$1.05 Billion |
|
Wave Life Sciences Ltd
NASDAQ:WVE
|
$1.05 Billion |
|
Air Transport Services Group Inc
NASDAQ:ATSG
|
$1.05 Billion |
|
Five9 Inc
NASDAQ:FIVN
|
$1.05 Billion |
|
SAGILITY INDIA LIMITED
NSE:SAGILITY
|
$1.05 Billion |
|
Global Health Limited
NSE:MEDANTA
|
$1.05 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oculis Holding AG Ordinary shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 93,728,000 to 73,383,000, a change of -20,345,000 (-21.7%).
- Net loss of 85,777,000 reduced equity.
- New share issuances of 53,541,000 increased equity.
- Other comprehensive income decreased equity by 1,105,000.
- Other factors increased equity by 12,996,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-85.78 Million | -116.89% |
| Share Issuances | $53.54 Million | +72.96% |
| Other Comprehensive Income | $-1.10 Million | -1.51% |
| Other Changes | $13.00 Million | +17.71% |
| Total Change | $- | -21.71% |
Book Value vs Market Value Analysis
This analysis compares Oculis Holding AG Ordinary shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 14.48x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-1.33 | $26.30 | x |
| 2021-12-31 | $-1.86 | $26.30 | x |
| 2022-12-31 | $-2.99 | $26.30 | x |
| 2023-12-31 | $3.13 | $26.30 | x |
| 2024-12-31 | $1.82 | $26.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oculis Holding AG Ordinary shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -116.89%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -12503.94%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.64x
- Recent ROE (-116.89%) is below the historical average (-42.33%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | -1497.78% | 0.06x | 0.00x | $-10.51 Million |
| 2021 | 0.00% | -1932.50% | 0.02x | 0.00x | $-12.46 Million |
| 2022 | 0.00% | -4243.20% | 0.02x | 0.00x | $-28.90 Million |
| 2023 | -94.74% | -10056.85% | 0.01x | 1.22x | $-98.17 Million |
| 2024 | -116.89% | -12503.94% | 0.01x | 1.64x | $-93.12 Million |
Industry Comparison
This section compares Oculis Holding AG Ordinary shares's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oculis Holding AG Ordinary shares (OCS) | $130.59 Million | 0.00% | 0.29x | $1.05 Billion |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |